Bayer is in an interesting turn around phase. The Bayer stock has dropped 50% in a year, down from €52 to €26. Bayer has several major problems. One major problem is lawsuits regarding Roundup, there seams to be potential to manage damages and a court has set down initial claims. An other major problem is within pharma, where patents for major drugs are expiring. The new CEO Bill Anderson is reorganising Bayer (with Dynamic Shared Ownership), reducing management layers with the goal of being a more result orientated and agile company. I see can see a negative scenario with a declining business. But I can also see a positive scenario where the CEO manages to cut costs and increase innovation and in that case the current share price is too low and could double over a some years.